Duobrii (Halobetasol Propion/Tazarotene) Patent Expiration, LOE Window & CMS Spending

Duobrii (Halobetasol Propion/Tazarotene) by Bausch Health: FDA Orange Book LOE 2036-06-06, 1 AB generics, $1.3M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBausch Health
FDA Application & PathwayN209354 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2036-06-06
Orange Book Patents (*PED Extensions)10 patents (0 *PED)
Active AB-Rated Generic Competitors1
2024 CMS Total Public Spend$1.3M
2024 Medicare Part D Spend$794K
2024 Medicaid Spend$526K
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 22.3% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bausch Health / Bausch + Lomb across sibling Meru public-data platforms.